APAC Infectious Disease Diagnostics Market

APAC Infectious Disease Diagnostics Market Size (2023 to 2028)

The Asia Pacific infectious disease diagnostics market is anticipated to grow at an 8.98% CAGR from 2023 to 2028. As a result, the market size is expected to grow from USD 3.19 billion in 2023 to USD 4.9 billion by 2028.

The growing number of people suffering from various infectious diseases such as malaria, influenza, sexually transmitted diseases such as HIV, and other bacterial infections is one of the major factors promoting the growth of the infectious disease diagnostics market in the Asia-Pacific region. The growing prevalence of infectious diseases in countries such as India and China is fueling the sales of diagnostic products in this region. According to the National Library of Medicine, curable infectious diseases were causing significant deaths in South Asia and accounted for 3.7 million deaths among children in 2020. The increasing focus of key market participants on tapping the potential of the Asia-Pacific region is boosting market growth. Manufacturers operating in this region focus on improving their product availability across the region by strengthening their distribution channels.

Growing investments to conduct R&D to develop technologically advanced and cost-effective solutions are further anticipated to favor the market growth in this region. Furthermore, the rapid technological advancements in developing countries such as India through the reorientation of business models towards a more consumer-centric approach made early molecular diagnostic tests available for other classes, too, instead of just the upper class. This has led to a massive increase in the purchasing power of the people driving the regional market growth. Furthermore, most infectious and non-communicable diseases are often not managed in an integrated manner in Asia-pacific, which paved the way for high-yield intervention screening programs for detecting non-communicable diseases or NCDs, which are further improved by investments in capacity development, data, technology, and public education, factors as such are expected to promote the market growth.

However, factors such as inadequate reimbursement scenarios, favorable behavior from the health insurance companies, and high costs associated with treating and maintaining infectious diseases diagnostic services are negatively impacting the market growth in this region. In addition, the lack of infrastructure in low- and middle-income countries, strict government restrictions, and lack of awareness regarding the available treatment options in developing countries further inhibit the market’s growth rate.

This research report on the APAC infectious disease diagnostics market has been segmented and sub-segmented into the following categories:

By Product: 

• Instruments
• Reagents
• Services
• Software

By Application: 

• Hepatitis B
• Hepatitis C
• Human Immunodeficiency Virus (HIV)
• Tuberculosis (TB)
• Chlamydia trachomatis
• Neisseria gonorrhoeae (CT/NG)
• Human papillomavirus (HPV)
• Methicillin-resistant Staphylococcus aureus (MRSA)
• and others (Influenza, Ebola, Typhoid, Malaria, and Dengue)

By Technology: 

• PCR
• INAAT
• DNA Sequencing
• Hybridization

By End User: 

• Hospital
• Laboratories

By Country: 

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

Geographically, Asia-Pacific is projected to register the highest growth rate during the forecast period due to the increased pervasiveness of infectious diseases and tremendous investment opportunities due to a growth in healthcare expenditure. Asia-Pacific has the highest prevalence of infectious diseases, such as tuberculosis (TB), hepatitis, and sexually transmitted infections (STIs). In addition, the large patient population, high demand for better healthcare facilities, and growing awareness of treatment options are boosting the market growth in this region.

China dominated the market, followed by India in 2022. The domination of China can be attributed to the massive population of patients suffering from bacterial infectious diseases, rising awareness of the early diagnosis of diseases with the help from an increasing number of activities by governments and private organizations, leading to increasing investment by healthcare providers to improve healthcare development and provision of better patient outcomes.

KEY MARKET PLAYERS:

A few of the notable companies operating in the APAC infectious disease diagnostics market profiled in the report are Abbott Laboratories, bioMérieux SA, Hologic, Inc., Danaher Corporation, Becton, Dickinson and Company, Cepheid, Inc., Thermo Fisher Scientific Inc., Roche Diagnostics, Alere Inc., DiaSorin S.p.A., Quidel Corporation, and Bio-Rad Laboratories, Inc.